Metformin in the Horse: Pharmacokinetics and Detection Times Using Monte Carlo Simulations.

Overview

• This study examined how the drug metformin, prohibited in racehorses, behaves in horses’ bodies after oral and intravenous administration.
• It used pharmacokinetic analysis and simulations to determine how long metformin remains detectable in blood and urine to inform racing anti-doping regulations.

Background and Purpose

• Metformin is a medication commonly prescribed to humans for diabetes, but it is banned in racehorses.
• Recent findings showed metformin present in post-race samples, raising questions about its metabolism, clearance, and detection windows in horses.
• The study aimed to characterize metformin’s pharmacokinetics (drug absorption, distribution, metabolism, elimination) and estimate detection times to guide regulatory withdrawal periods.

Study Design and Methods

• A randomized, balanced, two-way crossover design was used with 12 Thoroughbred horses.
• Each horse received metformin both orally and intravenously in different phases to compare absorption and elimination.
• Serum (blood) and urine samples were collected over time post-administration.
• Metformin concentrations were measured with liquid chromatography-tandem mass spectrometry (a sensitive method for drug detection).
• Pharmacokinetic analysis included:
  • Noncompartmental analysis – a straightforward method to estimate drug clearance and half-life without assuming body compartment models.
  • Population pharmacokinetic modeling – a statistical approach modeling variation across the horse population.
• Monte Carlo simulations modeled metformin disposition in a hypothetical population of 1000 horses to predict detection times probabilistically.

Key Findings

• Metformin serum concentration peaked on average at 941.0 ± 467.8 ng/mL after administration.
• The mean terminal half-life (time for the serum concentration to reduce by half in the elimination phase) was approximately 85.8 ± 15.1 hours, indicating slow clearance.
• Metformin levels dropped below the limit of quantification (LOQ, 0.25 ng/mL) by Day 11 in half of the horses and by Day 25 in all horses.
• Monte Carlo simulations showed that serum metformin concentrations would fall below the minimum reporting level (MRL) of 0.5 ng/mL after about 475 hours (~20 days) in 1000 simulated horses.
• Urine metformin concentrations showed high variability both between horses and within the same horse over time.
• There was no consistent correlation between urine and blood metformin concentrations throughout the sampling period.

Interpretation and Implications

• The prolonged half-life and persistence of metformin in blood suggest that the drug remains detectable for several weeks after administration.
• Regulatory authorities should consider longer withdrawal times to prevent unintentional positive doping tests if metformin has been administered.
• Due to inconsistent excretion patterns in urine, blood (serum) is a more reliable biological matrix for detecting metformin in anti-doping testing.
• Use of Monte Carlo simulations strengthens the generalizability of detection times by accounting for inter-individual variability.
• This research informs industry stakeholders, including veterinarians and racing regulators, about safe withdrawal intervals and choice of sample type to ensure fair competition and horse welfare.